Where to buy lorlatinib/lorlatinib

Lorlatinib is indicated only for the treatment of adult patients with ALK-positive NSCLC who have been diagnosed with advanced or metastatic NSCLC when the cancer has spread to lymph nodes (locally advanced disease) or other parts of the body (metastatic disease) and who have never received prior systemic therapy. Evidence from a clinical trial suggests that lorlatinib delays disease progression compared with crizotinib in patients with metastatic ALK-positive non-small cell lung cancer. Evidence suggests that lorlatinib is effective in treating and preventing brain metastases in patients with ALK-positive non-small cell lung cancer.

Lorlatinib is a selective adenosine triphosphate (ATP)-competitive small molecule that can penetrate the blood-brain barrier and inhibit ALK and ROS1 tyrosine kinases. Lorlatinib meets patients' needs for improved disease control by delaying disease progression and controllable side effects. The recommended dose is 100 mg, taken orally once daily. Adverse events in most categories were higher in patients treated with lorlatinib compared with crizotinib; however greater toxicities did not result in more dose adjustments and/or interruptions or discontinuation of treatment.

The original drug of lorlatinib has been launched in China and has been included in the national medical insurance reimbursement list. Patients who meet the indications can use medical insurance for reimbursement. This drug may be sold in domestic hospitals or pharmacies. Lorlatinib is a prescription drug, and patients must rely on their doctor's prescription information when purchasing. Currently, the original drug or generic drugs of Lorlatinib are also sold overseas. Their drug ingredients are basically the same, but the price of the generic drugs will be relatively cheaper. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.